Company Focus

Johnson & Johnson

Latest Johnson & Johnson News

Nanobiotix’ NBTXR3 secures reclassification in Europe
Biotechnology
French biotech Nanobiotix’ (shares were up nearly 7% at 4.44 euros in early trading, after the company announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica, a Johnson & Johnson subsidiary.   8 July 2025


Latest News & Features of interest to Johnson & Johnson

Latest Related Ones To Watch News

US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate CPTX2309, for up to $2.1 billion. Organon posted disappointing mid-stage trial results for its investigational endometriosis pain drug, OG-6219. Also of note last week, the US Food and drug Administration (FDA) granted accelerated approval for Regeneron’s multiple myeloma drug Lynozyfic.   6 July 2025

More in M&A >


Related Ones to Watch Companies

Reset all filters
Refine Search